A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients
Latest Information Update: 01 Aug 2024
At a glance
- Drugs 707 3SBio (Primary) ; Carboplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sunshine Guojian Pharmaceutical
Most Recent Events
- 30 Jul 2024 Status changed from not yet recruiting to recruiting.
- 17 May 2024 New trial record